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 economic beneﬁt between two different pneumococcal vaccines. Indirect costs were 
estimated for both vaccines according to the ﬁve approaches to assess the methodologi-
cal inﬂuence on the total disease cost difference between PCV-7 and PHiD-CV. Base-
line indirect cost estimates include the cost of productivity losses of paid workers due 
to disease, sequelae, and earlier death. Some of the approaches include in terms of 
cost: children’s future productivity losses, unpaid work loss and parents’ work loss, 
when looking after their sick children. RESULTS: Compared to FCM, HCM based 
approaches constantly generated higher estimates of indirect cost. Results of HCM 
ranged between a1.1bn (PHiD-CV), a1.2bn (PCV-7) and a1.9bn (both vaccines), while 
for FCM they ranged between a0.2bn and a0.9bna (both vaccines). Cost attributed 
to earlier death varied with a factor of 35; indirect cost due to earlier death as a pro-
portion of total indirect cost varied between 16% (conservative FCM) and 79% 
(conservative HCM). The overall impact on total disease cost differences between the 
two vaccines did not alter with any approach selected (PHiD-CV always dominates 
PCV-7), but the amount of savings signiﬁcantly differs depending on the used method. 
CONCLUSIONS: Although different approaches for estimating indirect cost have 
a huge impact on the cost difference between pneumococcal conjugate vaccines in  
Germany, the rating of these vaccines (PCV-7 dominated by PHiD-CV) stays unaf-          
fected. FCM always generates lower estimates than HCM.
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OBJECTIVES: To evaluate the clinical and economic impact of bacteremia caused by 
extended-spectrum beta-lactamases (ESBL) producing Escherichia coli. METHODS: 
A case-control study was conducted in a teaching hospital in Hong Kong. Case 
patients who had blood cultures positive for ESBL-producing E. coli were matched 
with patients who had bacteremia caused by non-ESBL-producing E. coli from 
January 2002 through December 2004. Demographic data, clinical factors and health 
care resource utilization for bacteremia were retrieved from medical records. Outcome 
measurements included mortality, infection-related cost and infection-related length 
of stay. RESULTS: Thirty-ﬁve case patients with ESBL-producing E. coli bacteremia 
were matched with 35 control patients with non-ESBL-producing E. coli bacteremia. 
The mortality rates were 8/35 (22.9%) in cases and 1/35 (2.9%) in controls. The 
average total cost for cases and controls were HK$51,100 o $44,292 and HK$30,300 
o $19,427 (USD1  HKD7.8), respectively. Mean infection-related length of stay in 
cases was 11.5 o 4.9 days and 8.4 o 5.2 days in controls. Multiple regression analysis 
showed that ESBL production was not signiﬁcantly associated with mortality, but it 
was a signiﬁcant predictor of infection-related cost (ME: 1.32; 95% CI  1.04–1.69; 
P  0.001) and infection-related length of stay (ME:1.42, 95% CI  1.16–1.73, P  
0.001). CONCLUSIONS: ESBL-production was associated with increased length of 
stay and direct medical cost for treatment of E. coli bacteremia.
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OBJECTIVES: Published clinical trials have shown similar clinical cure rates and 
shorter length of stay (LOS) for linezolid compared to vancomycin and teicoplanin in 
patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. The aim 
of this pharmacoeconomic evaluation was to assess the cost-effectiveness of linezolid 
vs. vancomycin and teicoplanin from the perspective of Czech health care system. 
METHODS: We have collected the data on health care resource utilisation in patients 
with MRSA infections treated with linezolid, vancomycin or teicoplanin (drug admin-
istration, monitoring, hospitalisations, adverse events). Costs from ofﬁcial price lists 
of health insurance companies were applied to all colected items. Total costs of line-
zolid, vancomycin and teicoplanin treatment course were compared. We have analysed 
two subsets of patients—with MRSA infections after surgery hospitalized in ortho-
paedic clinic and patients with complicated MRSA infection requiring intensive care. 
RESULTS: Total number of 74 patients was analysed according to resource use and 
costs. The mean length of stay in MRSA patients in ortopaedic surgery patients was 
36.7 days and the mean hospitalisation cost was 94,462 CZK (a3,633). The mean 
length of stay in MRSA intesive care patients was 45.2 days and the mean hospitalisa-
tion cost was 204,775 CZK (a7876). There was a tendency for shorter length of hos-
pitalisation in the group of linezolid patiens in comparison to teicoplanin patients 
(32.7 vs. 43.6 days). The increased antibiotic acquisition cost of linezolid (three time 
higher in comparison with vancomycin and two times higher in comparison with tei-
coplanin) was balanced by the estimated cost savings for hospitalisations, and addi-
tional savings in laboratory monitoring, concomitant medication and adverse events. 
CONCLUSIONS: Based on the patient-speciﬁc data linezolid is cost-effective option 
for hospitalised MRSA patients in Czech Republic. Despite higher acquisition cost the 
total hospitalisation costs are very similar to teicoplanin and vancomycin.
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OBJECTIVES: Compare the economic impact of prophylaxis with valganciclovir 
against cytomegalovirus (CMV) infection versus non-prophylactic decision, in renal 
transplantation recipients, for analysing cost of treatment. METHODS: Economic 
evaluation through a theoretical cost analysis to assess the impact of using prophylaxis 
with valganciclovir (450 mg every 12 h for 100 days) compared with no prophylaxis, 
in patients receiving a renal transplantation with high (D/R-) and intermediate (R) 
risk of CMV disease. Outcomes evaluated were secondary morbidity due to CMV 
infection, including organ rejection. Calculations about the referred complications 
were based on informed frequencies from medical literature. Costs were evaluated 
from the service provider perspective, in US dollars and include the resources used for 
prophylaxis and complications. Cost analysis results from the difference between 
symptomatic disease due to CMV, the cost of treating an acute rejection and the 
ﬁnancial pressure regarding both situations. The number of patients needed to treat 
(NPT) for achieving clinical success was calculated. RESULTS: Based on a hypotheti-
cal scenario of 1 thousand patients, equally distributed in each group, the frequency 
of symptomatic infection in the valganciclovir group would be 1% against to 31% in 
the non-prophylaxis group. The same tendency is kept regarding development of 
asymptomatic infection (4% vs. 32%) as well as organ rejection (1.5% vs 16.1%). 
CONCLUSIONS: With this theoretical pharmacoeconomic evaluation it is demon-
strated that the use of prophylaxis with valganciclovir might be a cost-saving alterna-
tive for a medium-term perspective, derived from reduction in the frequency of 
infections and indirect events related with CMV replication like organ rejection. In 
patients with intermediate risk (R), a comparison must be established between costs 
of prophylaxis and pre-emptive intervention, because the last might reduce medica-
tions consumption but increasing diagnosis and monitoring costs, as well as not 
avoiding indirect events related to viral replication.
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OBJECTIVES: The aim of this study is to calculate direct cost of management diabetic 
foot infection (DFI) due to MRSA in diabetes mellitus (DM) patient-population treated 
with linezolid and to identify the most important factors related to treatment costs. 
METHODS: A cost-study was performed with data from 70 prospectively patients 
with DFI treated with linezolid from-2006-to-2008 in 10 Spanish Hospitals included 
in a non-comparative clinical trial. Cost for in-patient-stay, and outpatient manage-
ment were calculated retrospectively from diagnosis until healing or death in those 
patients where the cost data could be estimated. Cost for linezolid treatment (IV-oral), 
IV administration and monitoring were also estimated. Resource utilization not col-
lected during the study was based on published literature. Cost data derived from lit-
erature and Spanish database. Mean values for each item were used to calculate cost 
average. All costs are expressed in Euros 2007. RESULTS: Mean age was 63.2 years 
old (SD 13.0), being 68.1% males. Duration of DM was 16.5 years. A total of 55 
patients healed without amputation (78.6%) and 9 (12.9%) healed after amputation. 
Total cost for a patient without amputation was a9429.7 (95% CI 8404.2–10455.3), 
while corresponding cost for a patient with amputation was a9949.9 (95% CI 6034.3–
13865.6). Hospitalization accounts for 54% of cost of treating DFI in patients without 
amputation and 48% in patients with amputation. Surgery cost was 17% of total cost 
in patients undergoing amputation. Drug costs didn’t account for the major part of 
costs incurred during in-patient phase. Outpatient costs were 5% and 7% of total cost 
in patients without and with amputation, respectively. CONCLUSIONS: These are 
the ﬁrst cost data results for DFI due to MRSA in Spain. Amputations were associated 
with high cost mainly due to surgery and long-term cost. These ﬁndings suggest the 
potential efﬁciency of a targeted approach program to prevent amputations in patients 
with DFI.
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OBJECTIVES: Whether combination antiviral therapy is cost-effective for patient with 
HCV in the real-world setting has not yet to be shown. This study is to compare the 
cost-effectiveness of combination antiviral therapy with no treatment in cirrhotic 
patients with q1 doses of combination prescriptions (base case), and with q48 weeks 
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continuous combination prescriptions (subgroup) from a managed care organization 
health care system perspective. METHODS: Using the Integrated Health Care Infor-
mation Services National Managed Care Benchmark Database from January 19997-
June 2007, we followed newly-diagnosed, HCV-infected patients with cirrhosis for 
the occurrence of end-staged liver diseases (ESLD), starting from the date of their 
ﬁrst prescriptions. For each patient, we measured effectiveness (Ei) as time to ESLD 
occurrence or censored, and costs (Ci) as the sum of pharmacy, outpatient and 
inpatient costs incurred in the follow up (2007 US dollars). Individual patient’s net 
beneﬁt was calculated as lambda times Ei minus Ci, and the net beneﬁt regression 
framework was employed to determine the cost-effectiveness of antiviral therapy and 
the importance of covariates on the incremental net beneﬁt of an intervention control-
ling for patient-related characteristics. The inverse probability of censored weighting 
technique was used to account for potential bias due to censored cost and effectiveness 
data. RESULTS: The results found that, at a number of lambda values qUS$10,000, 
combination antiviral therapy was more cost effective than no treatment in base case 
analysis. In subgroup analysis, continuous antiviral therapy was cost effective than 
no treatment at lambda value qUS$1000,000. Time of HCV diagnosis, HIV co-infec-
tion and prior gastroenterologist visits were potentially important covariates on 
the incremental net beneﬁt of treatment. CONCLUSIONS: From the standpoint of 
cost-effectiveness, continuation of antiviral therapy should consider the variability 
in early viral response because treatment beyond 12 weeks is no recommended 
for genotype 1, HCV-infected patients when achieving sustained viral response is 
unlikely.
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OBJECTIVES: To evaluate long-term cost-effectiveness of the treatment of CHB 
HBeAg-positive and -negative patients with telbivudine compared with lamivudine. 
METHODS: The study was conducted from China’s social health insurance perspec-
tive over a lifetime horizon using a Markov model. Individual patient data (age, 
gender, virological, serological and biochemical response and resistance to telbivudine 
versus lamivudine) after 104 weeks from the multinational GLOBE registration trial 
were applied. Disease progression from CHB to other health states was derived from 
literature. Economic outcomes, including China-speciﬁc data for life expectancy, 
utility and drug costs were applied. The annual medical expenditure was calculated 
with 599 community patients with CHB-related diseases in Beijing and Guangzhou 
cities of China and data were also retrieved from literature. Drug treatment of telbi-
vudine or lamivudine treatment is ceased upon achieving chronic hepatitis HBeAg-, 
HBsAg-. All costs were valued in Chinese-yuan, year 2007 values. Costs and outcomes 
were discounted at 3% per annum. Sensitivity analysis was conducted to evaluate 
uncertainty in study results. RESULTS: Compared with lamivudine, the incremental 
cost for 1 additional QALY gained with telbivudine in treating HBeAg-positive and 
-negative CHB were 13,361 yuan (US$1,965) and 62,999 yuan (US$9,265) in Beijing, 
as well 12,078 yuan (US$1,776) and 65,864 yuan (US$9,686) in Guangzhou, respec-
tively. According to national economic burden of CHB-related diseases retrieved from 
literature, the ICER with telbivudine vs lamivudine were 3,170 yuan (US$466) and 
70,420 yuan (US$10,356) for HBeAg-positive and -negative CHB, respectively. CON-
CLUSIONS: Among CHB patients, treatment with telbivudine is cost effective as 
compared to lamivudine, based on the World Health Organization’s recommended 
maximum willingness to pay threshold.
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OBJECTIVES: Rotavirus (RV) is a major cause of gastroenteritis (GE) in infants but 
can be prevented by vaccination. The study objective was to estimate the cost effective-
ness of universal rotavirus vaccination of infants from an Irish Healthcare payer per-
spective. METHODS: A published Markov model, calibrated to observed Irish 
epidemiological data was used. A cohort of 70,600 newborns was followed over ﬁve 
years during which the seasonality of infection and protective effects of breastfeeding 
were captured. Routine vaccination with the oral 2- dose vaccine RIX 4414 was 
compared with no vaccination. Efﬁcacy from a European phase-III trial (102247) 
showed 96% and 86% against severe RVGE and 100% and 92% against hospitalisa-
tions due to RV in the ﬁrst and second years post vaccination respectively. Costs were 
from published sources in 2007 prices. Utilities came from a UK study of physician 
scores using the EQ-5D questionnaire. Costs and effects, discounted at 3.5%, were 
assessed over lifetime. Sensitivity analyses were conducted. RESULTS: The model 
estimated that 14,700 GP visits, 4,000 A&E visits, 3,400 hospitalisations and 840 
nosocomial cases occurred in the birth cohort at a cost of a7.3m. With a coverage 
rate of 87% the number of GP and hospital visits could be reduced by 82% with 
vaccination. Cost effectiveness was estimated at a29,398 per QALY. These results 
were driven by the high rate of hospitalisation due to RV. The results were most sensi-
tive to the cost of vaccination and hospitalisations, incidence of RV and hospitalisa-
tions and the discount rate. CONCLUSIONS: Rotavirus imposes a signiﬁcant ﬁnancial 
burden on the Irish health care system. Universal vaccination of infants is a cost-
 effective approach to reducing this burden.
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OBJECTIVES: To estimate the clinical and economic impact of vaccinating a birth 
cohort with the newly licensed 10-valent pneumococcal non-typeable haemophilus 
inﬂuenzae protein-D conjugate vaccine (PHiD-CV) compared with the 13-valent pneu-
mococcal candidate vaccine (PCV-13) over lifetime. METHODS: We developed an 
age-compartmental, deterministic, and static Markov model to project the impact of 
pneumococcal vaccination on the incidence of pneumococcal infections from birth 
through lifetime in speciﬁc age–time units (months). The disease types modeled include 
invasive pneumococcal disease (IPD), community acquired pneumonia (CAP) and 
acute otitis media (AOM), assuming 11 health states per condition. Serotype distribu-
tions per disease type and age group were incorporated. Costs, health gains and cost-
effectiveness were estimated. A 4-dose (31) schedule is assumed for both vaccines 
with 100% vaccine coverage. All analyses were performed from the Canadian health 
care system perspective assuming a price parity of $70 per dose. The model uses 
Canada speciﬁc epidemiological data. Both outcomes and cost were discounted at 
3.5%. Various sensitivity analyses were performed to assess the impact of changes in 
the key assumptions of the model. RESULTS: Compared with PCV-13, vaccinating a 
birth cohort of 340,000 with PHiD-CV in Canada is expected to prevent 92,026 
additional AOM myringotomies and 108,978 ambulatory visits due to AOM over 
lifetime. The impact of the two vaccines on IPD is projected to be comparable. At 
price parity of $70 per dose, the total savings to the Canadian health care system over 
the lifetime of the cohort is projected to be $58.7M for PHiD-CV compared to PCV-
13. Sensitivity analyses indicate that AOM and bacteraemia have the biggest impact 
on the model. CONCLUSIONS: Overall, the clinical beneﬁts of the two vaccines are 
comparable on IPD. QALYs are improved for PHiD-CV compared to PCV-13 because 
of the greater impact on AOM. PHiD-CV is projected to be cost-saving to the Cana-
dian health care system compared to PCV-13.
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OBJECTIVES: To determine the cost-effectiveness of pneumococcal non-typeable 
Haemophilus inﬂuenzae protein-D conjugate vaccine (PHiD-CV) when compared with 
7-valent pneumococcal conjugate vaccine (PCV-7) and with no vaccination for the 
prophylaxis of invasive (ID) and non-invasive pneumococcal diseases in Poland. 
METHODS: A Markov cohort model was used with a starting birth cohort of 393 
506 infants. The Streptococcus pneumoniae serotype distribution from Czech Repub-
lic setting was selected as a proxy for Polish data. The effectiveness and safety data 
came from a meta-analysis of clinical trial results. Limited cross-protection of sero-
types 6A and 19A, herd protection and serotype replacement were included into the 
model design. Ten years time horizon (the period of direct vaccine effect) and 96% 
vaccine coverage rate were considered. Direct medical costs were collected during 
January-March, 2009 from a public payer’s and patient’s perspective. Price parity 
between vaccines was assumed. Sensitivity analysis was carried out. Annual discount 
rate for cost and effect was 5.0% and 3.5% respectively. RESULTS: Base-case analysis 
of PHiD-CV shows that mass vaccination of the birth cohort reduced the number of 
ID by 120, pneumonia by 17,102, and acute otitis media events by 113,768 cases over 
10 years. When compared with PCV-7 and no vaccination, PHiD-CV offered a Quality 
Adjusted Life Year gain (QALY) of 0.0045 and 0.0068 per vaccinated child respec-
tively. Prophylaxis with PHiD-CV instead of PCV-7 induced cost savings of 39.97 PLN 
per child. Vaccination with PHiD-CV dominated PCV-7 but when compared with no 
vaccination an incremental cost per QALY was estimated at 54,549 PLN. Sensitivity 
analysis showed consistency in the results. A few analysis limitations were identiﬁed 
such as length of vaccine protection and reliable serotype distribution data. CONCLU-
SIONS: Compared with no vaccination the model indicates that PHiD-CV is cost-
effective in Poland and has superior economic proﬁle to PCV-7.
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OBJECTIVES: National 7-valent pneumococcal vaccination (PCV7) was introduced 
in Greece in 2006. In May 2009 a 10-valent (PCV10) vaccine became available. A 
13-valent (PCV13) vaccine is expected in late 2009. This study aims to assess the 
clinical and economic beneﬁts of national immunization with PCV13 compared to 
PCV7 and PCV10 from the national health system perspective. METHODS: Using an 
